Fosun Pharma (600196, 02196) Announces Subsidiary’s Tetracaine Hydrochloride Gel Registration Accepted

Bulletin Express02-10 17:45

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196, 02196) announced that a drug registration application for Tetracaine Hydrochloride Gel, filed by its subsidiary Shanghai Zhaohui Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. The product is intended for percutaneous local anesthesia prior to venepuncture or venous cannulation and covers adults as well as infants aged over one month.

According to publicly disclosed figures, cumulative research and development investment in this project reached approximately RMB7.19 million as of December 2025. Industry data from IQVIA show that sales of similar Tetracaine Hydrochloride Gel formulations in China reached about RMB443 million in 2024, reflecting potential market demand for topical anesthetic products.

The acceptance of the application does not immediately guarantee commercial production, as further steps—including passing GMP compliance inspections—are required before final approval. The actual market impact of the product will depend on factors such as medical demand, competition, and distribution channels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132354413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132354413","market":"us","top_or_hot":-1,"title":"Fosun Pharma (600196, 02196) Announces Subsidiary’s Tetracaine Hydrochloride Gel Registration Accepted","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196, 02196) announced that a drug registration application for Tetracaine Hydrochloride Gel, filed by its subsidiary Shanghai Zhaohui Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. The product is intended for percutaneous local anesthesia prior to venepuncture or venous cannulation and covers adults as well as infants aged over one month.</p>\n<p>According to publicly disclosed figures, cumulative research and development investment in this project reached approximately RMB7.19 million as of December 2025. Industry data from IQVIA show that sales of similar Tetracaine Hydrochloride Gel formulations in China reached about RMB443 million in 2024, reflecting potential market demand for topical anesthetic products.</p>\n<p>The acceptance of the application does not immediately guarantee commercial production, as further steps—including passing GMP compliance inspections—are required before final approval. The actual market impact of the product will depend on factors such as medical demand, competition, and distribution channels.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (600196, 02196) Announces Subsidiary’s Tetracaine Hydrochloride Gel Registration Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (600196, 02196) Announces Subsidiary’s Tetracaine Hydrochloride Gel Registration Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-10 17:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196, 02196) announced that a drug registration application for Tetracaine Hydrochloride Gel, filed by its subsidiary Shanghai Zhaohui Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. The product is intended for percutaneous local anesthesia prior to venepuncture or venous cannulation and covers adults as well as infants aged over one month.</p>\n<p>According to publicly disclosed figures, cumulative research and development investment in this project reached approximately RMB7.19 million as of December 2025. Industry data from IQVIA show that sales of similar Tetracaine Hydrochloride Gel formulations in China reached about RMB443 million in 2024, reflecting potential market demand for topical anesthetic products.</p>\n<p>The acceptance of the application does not immediately guarantee commercial production, as further steps—including passing GMP compliance inspections—are required before final approval. The actual market impact of the product will depend on factors such as medical demand, competition, and distribution channels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1132354413","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132354413","pubTimestamp":1770716745,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196, 02196) announced that a drug registration application for Tetracaine Hydrochloride Gel, filed by its subsidiary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(600196, 02196)公告子公司盐酸丁卡因凝胶注册获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196, 02196) announced that a drug registration application for Tetracaine Hydrochloride Gel, filed by its subsidiary Shanghai Zhaohui Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. The product is intended for percutaneous local anesthesia prior to venepuncture or venous cannulation and covers adults as well as infants aged over one month.\nAccording to publicly disclosed figures, cumulative research and development investment in this project reached approximately RMB7.19 million as of December 2025. Industry data from IQVIA show that sales of similar Tetracaine Hydrochloride Gel formulations in China reached about RMB443 million in 2024, reflecting potential market demand for topical anesthetic products.\nThe acceptance of the application does not immediately guarantee commercial production, as further steps—including passing GMP compliance inspections—are required before final approval. The actual market impact of the product will depend on factors such as medical demand, competition, and distribution channels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132354413","isCrawlerRequest":true}